Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Board Member Bought Over $300,000 of Abbott Labs

Abbott’s peers include Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), Bristol Myers Squibb Co. (NYSE:BMY), and Teva Pharmaceutical Industries Ltd (NYSE:TEVA). There is a very wide spread of forward earnings multiples in this peer group. Teva appears the cheapest from that perspective, with the current pricing and analyst expectations actually giving it a five-year PEG ratio slightly less than 1, but Johnson & Johnson and Merck have forward P/Es in the 11-13 range and those are considerably larger companies. However, in each of these cases the sell-side’s expectations are generally for very strong earnings growth and so we would be careful of taking the attractive earnings multiples at face value. In terms of dividends, Merck and Bristol Myers Squibb stand out for yields of roughly 4%; betas are also low, and Bristol Myers Squibb in particular has almost no correlation with broader market indices at a beta of 0.1. Of course as might be expected for pharmaceutical companies exposure to the overall economy is limited in all cases.

It’s fairly easy to evaluate Abbott Labs from an income perspective: ignore it and instead focus on higher-yielding pharmaceutical companies such as Merck and Bristol-Myers Squibb. In terms of value we do think that the stock has some positive aspects, as revenue and operating income have been up and the P/E multiples look good. It certainly seems that it might be competitive with peers such as Teva, Johnson & Johnson, and Merck though those companies have high expected earnings growth that might make them worth looking into.

Disclosure: I own no shares of any stocks mentioned in this article.

Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!